Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Nicki Vasquez Biography and Net Worth

Insider of Sutro Biopharma

Dr. Vasquez has 25 years of biopharmaceutical discovery research and development experience and has lead our alliance and portfolio management since 2015. Prior to joining Sutro, she was Vice President of Program & Portfolio Management at StemCells, Inc., where she was responsible for establishing project management of research and clinical stage programs exploring HuCNS-SC stem cell therapy for Alzheimer’s Disease, spinal cord injury and dry AMD. Prior to that she was at Elan, where she held positions of increasing responsibility from Alzheimer’s Disease and autoimmune discovery research, to Vice President Research Operations & Program Management, and Vice President Development Program & Portfolio Management. Dr. Vasquez obtained her doctoral degree in immunology from the University of California, San Diego, and received her post-doctoral training at Genentech.

What is Nicki Vasquez's net worth?: The estimated net worth of Nicki Vasquez is at least $25,221.91 as of January 29th, 2024. Dr. Vasquez owns 12,803 shares of Sutro Biopharma stock worth more than $25,222 as of December 26th. This net worth approximation does not reflect any other assets that Dr. Vasquez may own. Learn More about Nicki Vasquez's net worth.
How old is Nicki Vasquez?: Dr. Vasquez is currently 61 years old. There are 6 older executives and no younger executives at Sutro Biopharma. The oldest executive at Sutro Biopharma is Ms. Linda A. Fitzpatrick, Chief People & Communications Officer, who is 67 years old. Learn More on Nicki Vasquez's age.
How do I contact Nicki Vasquez?: The corporate mailing address for Dr. Vasquez and other Sutro Biopharma executives is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. Sutro Biopharma can also be reached via phone at (650) 392-8412 and via email at [email protected]. Learn More on Nicki Vasquez's contact information.
Has Nicki Vasquez been buying or selling shares of Sutro Biopharma?: Nicki Vasquez has not been actively trading shares of Sutro Biopharma in the last ninety days. Most recently, Nicki Vasquez sold 12,185 shares of the business's stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a transaction totalling $60,925.00. Following the completion of the sale, the insider now directly owns 12,803 shares of the company's stock, valued at $64,015. Learn More on Nicki Vasquez's trading history.
Are insiders buying or selling shares of Sutro Biopharma?: During the last year, insiders at the sold shares 1 times. They sold a total of 12,185 shares worth more than $60,925.00. The most recent insider tranaction occured on January, 29th when insider Nicki Vasquez sold 12,185 shares worth more than $60,925.00. Insiders at Sutro Biopharma own 5.9% of the company. Learn More about insider trades at Sutro Biopharma.
Information on this page was last updated on 1/29/2024.

Nicki Vasquez Insider Trading History at Sutro Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/29/2024	Sell	12,185	$5.00	$60,925.00	12,803
9/28/2021	Sell	3,906	$18.62	$72,729.72

Nicki Vasquez Buying and Selling Activity at Sutro Biopharma

Sutro Biopharma Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.97

$1.85

$1.97

50 Day Range

MA: $2.95

$1.82

$4.40

2 Week Range

Now: $1.97

$1.70

$6.13

Volume

560,330 shs

Average Volume

866,438 shs

Market Capitalization

$162.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.